CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 90 enrolled
Drug / intervention
Kenalog +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02767492
NCT02767492N/ACompleted

A Double-blind, Randomized Study Comparing Steroid Injection and BioDRestore for Patients With Knee Osteoarthritis

The Hawkins Foundation·interventional·Posted May 10, 2016·Updated Nov 23, 2021

In Brief

A clinical study evaluating BioD Restore and Kenalog for Knee Osteoarthritis. Completed, enrolled 90 participants across 1 site.

Detailed Summary

This study will include patients who are diagnosed with knee OA and are recommended for a knee injection. Study subjects will be randomized to receive either the standard of care knee injection (steroid) or amniotic tissue injection (BioDRestore). Study subjects will be asked for permission for a baseline knee aspiration prior to the knee injection. At 6 months post-injection, knee aspirations will be taken and sent for analysis. Study subjects will be followed for 1 year post-injection to include range of motion measurements and patient-reported pain/functional outcome measurements. X-rays will also be taken at the 1-year post-injection appointment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 10, 2016
Enrollment StartJan 1, 2017
Primary CompletionJan 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 10.1 years ago

Interventions

BioD Restoredevice

Investigational product, BioD Restore, will be injected into the articular space of the knee.

Kenalogdrug

Active comparator, Kenalog steroid, will be injected into the articular space of the knee.